| OAA0102 | Low levels of intact proviral DNA in HIV elite controllers associate with cell-associated HIV RNA and protective HLA alleles | Oral abstract session with live Q&A | A4 |
| OAA0103 | In-depth characterization of full-length archived HIV genomes in long-term post-treatment and natural HIV controllers (ANRS CODEX/iVISCONTI Cohort) | Oral abstract session with live Q&A | A4 |
| OAA0106 | Virological and immunological evaluation of individuals with spontaneous persistent viral control without ART | Oral abstract session with live Q&A | A4 |
| PEA0019 | Strengths and trials for translational research-to-policy developments in Uganda | E-poster | A4 |
| PEA0020 | Characterization of Gag mutations in HIV-1 subtype A long-term non-progressors | E-poster | A4 |
| PEA0083 | Dose adjustment of doravirine mitigates the pharmacokinetic interaction with the moderate CYP3A inducer, rifabutin | E-poster | A34 |
| PEA0084 | Effects of INSTI and other ARV combinations on folate distribution via folate transporters: Implications for neural tube defects | E-poster | A34 |
| PEA0085 | Targeting tipranavir to mesenteric lymph nodes (MLNs) for improved treatment of HIV/AIDS | E-poster | A34 |
| PEA0086 | Use of traditional medicines and effect of clay-based remedies in pregnant HIV-positive women | E-poster | A34 |
| PEA0087 | Pharmacokinetics and safety of long-acting tenofovir alafenamide implants in macaques for HIV prevention | E-poster | A34 |